Literature DB >> 11689642

Replication-defective vector based on a chimpanzee adenovirus.

S F Farina1, G P Gao, Z Q Xiang, J J Rux, R M Burnett, M R Alvira, J Marsh, H C Ertl, J M Wilson.   

Abstract

An adenovirus previously isolated from a mesenteric lymph node from a chimpanzee was fully sequenced and found to be similar in overall structure to human adenoviruses. The genome of this virus, called C68, is 36,521 bp in length and is most similar to subgroup E of human adenovirus, with 90% identity in most adenovirus type 4 open reading frames that have been sequenced. Substantial differences in the hexon hypervariable regions were noted between C68 and other known adenoviruses, including adenovirus type 4. Neutralizing antibodies to C68 were highly prevalent in sera from a population of chimpanzees, while sera from humans and rhesus monkeys failed to neutralize C68. Furthermore, infection with C68 was not neutralized from sera of mice immunized with human adenovirus serotypes 2, 4, 5, 7, and 12. A replication-defective version of C68 was created by replacing the E1a and E1b genes with a minigene cassette; this vector was efficiently transcomplemented by the E1 region of human adenovirus type 5. C68 vector transduced a number of human and murine cell lines. This nonhuman adenoviral vector is sufficiently similar to human serotypes to allow growth in 293 cells and transduction of cells expressing the coxsackievirus and adenovirus receptor. As it is dissimilar in regions such as the hexon hypervariable domains, C68 vector avoids significant cross-neutralization by sera directed against human serotypes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689642      PMCID: PMC114747          DOI: 10.1128/JVI.75.23.11603-11613.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  High throughput method for creating and screening recombinant adenoviruses.

Authors:  A R Davis; K Meyers; J M Wilson
Journal:  Gene Ther       Date:  1998-08       Impact factor: 5.250

3.  Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon.

Authors:  J J Rux; R M Burnett
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

4.  Improved adenovirus vectors for infection of cardiovascular tissues.

Authors:  M J Havenga; A A Lemckert; J M Grimbergen; R Vogels; L G Huisman; D Valerio; A Bout; P H Quax
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

6.  Characterization of four new adenovirus serotypes isolated from chimpanzee tissue explants.

Authors:  M Basnight; N G Rogers; C J Gibbs; D C Gajdusek
Journal:  Am J Epidemiol       Date:  1971-08       Impact factor: 4.897

7.  Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E.

Authors:  P Ostapchuk; P Hearing
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products.

Authors:  M Christ; B Louis; F Stoeckel; A Dieterle; L Grave; D Dreyer; J Kintz; D Ali Hadji; M Lusky; M Mehtali
Journal:  Hum Gene Ther       Date:  2000-02-10       Impact factor: 5.695

9.  Immunological relationship among adenoviruses of humans, simians, and nonprimates as determined by the neutralization test.

Authors:  H F Willimzik; S S Kalter; T L Lester; R Wigand
Journal:  Intervirology       Date:  1981       Impact factor: 1.763

10.  Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype.

Authors:  J G Gall; R G Crystal; E Falck-Pedersen
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  97 in total

1.  Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity.

Authors:  Andrei N Varnavski; Yi Zhang; Michael Schnell; John Tazelaar; Jean-Pierre Louboutin; Qian-Chun Yu; Adam Bagg; Guang-ping Gao; James M Wilson
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 3.  Challenges in the search for an HIV vaccine.

Authors:  Angelique A C Lemckert; Jaap Goudsmit; Dan H Barouch
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

4.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 6.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

7.  HIV-1 vaccine development: progress and prospects.

Authors:  Anna R Thorner; Dan H Barouch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

8.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 10.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.